Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

Blood (2025) 146 (19): 2350–2356.

https://doi.org/10.1182/blood.2025028985

Published: 2025

Includes: Supplemental data

Journal Articles

Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry

Vivian Li, Rita Yim, Paul Lee, Qi Zhang, Lynn Chin, Po Yan Chan, Chun Kei Au, Sharon Shi, Lester Au, Carmen Lee, Tony Wu, Garret Leung, Yok-Lam Kwong, Harinder Gill

Blood (2025) 146 (Supplement 1): 2041.

https://doi.org/10.1182/blood-2025-2041

Published: 2025

Journal Articles

FLT3L-based conjugate targets chemoresistant leukemia stem cells via cell cycle re-entry in Acute Myeloid Leukemia

Dengyang Zhang, Yao Guo, Zhiyong Peng, Yan Xiao, Zhiguang Chang, Liuting Yu, Yuming Zhao, Qi Zhang, Lingling Ma, Shuping Li, Chi Kong Li, Kam Tong Leung, Zhizhuang Zhao, Chun Chen, Yun Chen

Blood (2025) 146 (Supplement 1): 319.

https://doi.org/10.1182/blood-2025-319

Published: 2025

Journal Articles

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma

Juan Du, Wanting Qiang, Jing Lu, Yanchun Jia, Haiyan He, Jin Liu, Pei Guo, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Nina Shah, Qi Zhang, Lianjun Shen, Jia Liu

Blood (2025) 146 (Supplement 1): 258.

https://doi.org/10.1182/blood-2025-258

Published: 2025

Journal Articles

From mechanistic synergy to clinical breakthrough: Updated results from a phase II Trial of HD-MTX, selinexor, and zanubrutinib in CNS lymphoma

Li Li, Bing Pan, Kaiyi Liu, Wenjing Yang, Xin Gao, Qi Zhang, Zhijia Zhao, Yinuo Cai, Xiaobo Wang

Blood (2025) 146 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2025-3550

Published: 2025

Journal Articles

Enhanced vsvg variants for binder‑dependent and high‑specificity transduction of primary T cells

kaiyuan wang, xiaoling wang, wancheng yang, Jiapan Hu, yixuan zhou, qi zhang, xuqiang kong, hao wang, peng zhang, yingyong xu, Jianxiang Wang, Ying Wang, Luhan Yang

Blood (2025) 146 (Supplement 1): 4181.

https://doi.org/10.1182/blood-2025-4181

Published: 2025

Journal Articles

USP25-Mediated Talin-1 Stabilization in Platelets: A Novel Mechanism of Hyperreactivity and Thrombosis Risk During Aging

Xuemei Jia, Shuoyi Jiang, Hong Cheng, zhicheng wang, Zhihan Chen, weiguo Dong, Haoxuan Zhong, Qi Zhang, Xianmin Song, Si Zhang, Rong Xia

Blood blood.2023023352.

https://doi.org/10.1182/blood.2023023352

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2 -mutated post-MPN AML

Blood (2025) 146 (3): 341–355.

https://doi.org/10.1182/blood.2024027117

Published: 2025

Includes: Supplemental data

Journal Articles

N-homocysteinylation of β-arrestins biases GPCR signaling and promotes platelet activation

Blood (2025) 145 (20): 2374–2389.

https://doi.org/10.1182/blood.2024025593

Published: 2025

Includes: Supplemental data

Journal Articles

Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients

Juan Du, Wanting Qiang, Jing Lu, Yanchun Jia, Haiyan He, Jin Liu, Pei Guo, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Nina Shah, Qi Zhang, Jia Liu, Lihong Weng, Lianjun Shen, Wei Cao

Blood (2024) 144 (Supplement 1): 2072.

https://doi.org/10.1182/blood-2024-204774

Published: 2024

Journal Articles

Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

Harinder Gill, Lester Au, Dorothy Tsai, Rita Yim, Vivian Li, Paul Lee, Lynn Chin, Qi Zhang, Garret Man Kit Leung, Tony Kwun Yat Wu, Hugh Young Rienhoff, Jr.

Blood (2024) 144 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2024-208038

Published: 2024

Journal Articles

Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations

Zhe Wang, Cassandra L. Ramage, Helen Ma, Haichao Zhang, Andrew Souers, Darren C Phillips, Marina Konopleva, Qi Zhang Tatarata

Blood (2024) 144 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2024-193405

Published: 2024

Journal Articles

ERK1/2 Inhibition Mediates Bax Dependent Proteolysis of OPA1 and Induces Mitochondrial Cristae Remodeling to Overcome Resistance to Venetoclax

Priyanka Sharma, Natalia Baran, Qi Zhang, M. Anna Zal, Joanne Munck, Martin Sims, Bing Z. Carter, Michael Andreeff, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 2759.

https://doi.org/10.1182/blood-2024-210698

Published: 2024

Journal Articles

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

Zhe WANG, Xufeng Chen, Simone Sidoli, Anna Skwarska, Yannan Jia, Lei Yang, Varun Gupta, Shikhar Sharma, Iannis Aifantis, Hussein A. Abbas, Naval Daver, Qi Zhang Tatarata, Marina Konopleva

Blood (2024) 144 (Supplement 1): 207.

https://doi.org/10.1182/blood-2024-198057

Published: 2024

Journal Articles

Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia

Dhabya Majid, Zhe WANG, Bin Yuan, Mhd Yousuf Yassouf, Amanda Schalk, Basant T. Gamal, Qi Zhang Tatarata, Jessica Lynn Root, Araceli Isabella Garza, Annie Hoai Nguyen, Sammy Ferri-Borgogno, Patrick K. Reville, Arnon Lavie, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 2777.

https://doi.org/10.1182/blood-2024-203584

Published: 2024

Journal Articles

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Blood (2024) 144 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2024-194031

Published: 2024

Journal Articles

Application of Transfer Learning to Recognize Early Death Myeloma Patients Based on Plasma Cell Morphology

Zhaochen Zhang, Zhangzhen Shi, Xiangyi Guo, Qi Zhang, Di Zhou, Lintao Bi

Blood (2024) 144 (Supplement 1): 6933.

https://doi.org/10.1182/blood-2024-207409

Published: 2024

Journal Articles

Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience

Li Li, Yan Ma, Xiaobo Wang, Zhiming Li, Zhiguang Lin, Qi Zhang, Jay Mei, Jingjing Ma, Xin Gao, Hui Kang, Zhijia Zhao, Hang Yang, Qing Li, Mengxue Zhang, Yingbo Zhou, Bobin Chen

Blood (2023) 142 (Supplement 1): 6301.

https://doi.org/10.1182/blood-2023-184682

Published: 2023

Journal Articles

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du, Wanting Qiang, Jing Lu, Yanchun Jia, Haiyan He, Jin Liu, Pei Guo, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Jia Liu, Qi Zhang, Lianjun Shen, Lihong Weng, Wenling Li, Wei Cao

Blood (2023) 142 (Supplement 1): 1022.

https://doi.org/10.1182/blood-2023-174841

Published: 2023

Journal Articles

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Anna Skwarska, Vinitha Mary Kuruvilla, Qi Zhang, Sovira Chaudhry, Naval Daver, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Deepa Sampath, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2023-187018

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax plus gilteritinib is effective in preclinical models of FLT3 -mutant BCL11B-a lineage-ambiguous leukemia

Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry

FLT3L-based conjugate targets chemoresistant leukemia stem cells via cell cycle re-entry in Acute Myeloid Leukemia

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma

From mechanistic synergy to clinical breakthrough: Updated results from a phase II Trial of HD-MTX, selinexor, and zanubrutinib in CNS lymphoma

Enhanced vsvg variants for binder‑dependent and high‑specificity transduction of primary T cells

USP25-Mediated Talin-1 Stabilization in Platelets: A Novel Mechanism of Hyperreactivity and Thrombosis Risk During Aging

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2 -mutated post-MPN AML

N-homocysteinylation of β-arrestins biases GPCR signaling and promotes platelet activation

Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients

Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

Anti-Leukemia Combinatorial Efficacy of ABBV155, a B7H3-BCL-XL Inhibitor Antibody-Drug Conjugate, in Combination with Venetoclax through BCL-XL/BIM and BCL-2/BIM Complex Dissociations

ERK1/2 Inhibition Mediates Bax Dependent Proteolysis of OPA1 and Induces Mitochondrial Cristae Remodeling to Overcome Resistance to Venetoclax

Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy

Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Application of Transfer Learning to Recognize Early Death Myeloma Patients Based on Plasma Cell Morphology

Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only